Moleculin Biotech (NASDAQ:MBRX – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $4.00 target price on the stock.
Other equities analysts have also issued research reports about the stock. Wall Street Zen upgraded shares of Moleculin Biotech to a “sell” rating in a research report on Wednesday, March 26th. Maxim Group upgraded shares of Moleculin Biotech from a “hold” rating to a “buy” rating and set a $4.00 price target for the company in a research report on Tuesday, March 25th.
View Our Latest Stock Report on Moleculin Biotech
Moleculin Biotech Trading Down 12.9%
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.02. During the same quarter in the prior year, the business posted ($2.02) earnings per share. Equities research analysts forecast that Moleculin Biotech will post -7.98 EPS for the current year.
Institutional Investors Weigh In On Moleculin Biotech
An institutional investor recently raised its position in Moleculin Biotech stock. Armistice Capital LLC raised its holdings in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX – Free Report) by 293.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,250,000 shares of the company’s stock after purchasing an additional 932,414 shares during the quarter. Armistice Capital LLC owned approximately 8.93% of Moleculin Biotech worth $1,217,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 15.52% of the company’s stock.
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Featured Stories
- Five stocks we like better than Moleculin Biotech
- How Can Investors Benefit From After-Hours Trading
- Robinhood Director Sells Millions, But HOOD Stock Eyes Gains
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill
- Differences Between Momentum Investing and Long Term Investing
- Super Micro Computer Stock’s Rally Backed by Strong Financials
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.